MASH/MASLD Screening Discussions Post-Resmetirom Approval

This HCPLive peer-to-peer discussion in hepatology takes aim at describing on the impact of resmetirom’s approval for management of NASH, now known as MASH. In this discussion, a pair of hepatologists from Canada and the UK offer their own perspective on how the approval will change discussions on both treatment and screening. In their conversation, the duo of Rajarshi Banerjee, MD, PhD, MSc, and Juan Pablo Arab, MD, touch upon the change in nomenclature from NASH to MASH, screening challenges, the MAESTRO-NASH trial, applying the data to real-world patients, and how therapies have altered discussions around screening.
www.hcplive.co...

[@user-qv5yy7kn1x]

When it comes to India